SIGA Technologies Inc (SIGA) - Total Assets
Based on the latest financial reports, SIGA Technologies Inc (SIGA) holds total assets worth $219.39 Trillion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check SIGA Technologies Inc (SIGA) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
SIGA Technologies Inc - Total Assets Trend (1996–2025)
This chart illustrates how SIGA Technologies Inc's total assets have evolved over time, based on quarterly financial data. Check SIGA Technologies Inc (SIGA) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
SIGA Technologies Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
SIGA Technologies Inc's total assets of $219.39 Trillion consist of 97.0% current assets and 3.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 70.6% |
| Accounts Receivable | $3.26 Million | 1.5% |
| Inventory | $49.05 Million | 22.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $898.33K | 0.4% |
Asset Composition Trend (1996–2025)
This chart illustrates how SIGA Technologies Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SIGA Technologies Inc (SIGA) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SIGA Technologies Inc's current assets represent 97.0% of total assets in 2025, an increase from 83.3% in 1996.
- Cash Position: Cash and equivalents constituted 70.6% of total assets in 2025, up from 0.0% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1996.
- Asset Diversification: The largest asset category is inventory at 22.4% of total assets.
SIGA Technologies Inc Competitors by Total Assets
Key competitors of SIGA Technologies Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs585.02 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
USA | $392.01 Million |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs8.94 Billion |
SIGA Technologies Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.25 | 8.40 | 15.94 |
| Quick Ratio | 2.38 | 6.28 | 13.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $146.37 Trillion | $205.82 Million | $119.10 Million |
SIGA Technologies Inc - Advanced Valuation Insights
This section examines the relationship between SIGA Technologies Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.67 |
| Latest Market Cap to Assets Ratio | 1.41 |
| Asset Growth Rate (YoY) | -10.2% |
| Total Assets | $219.47 Million |
| Market Capitalization | $308.41 Million USD |
Valuation Analysis
Above Book Valuation: The market values SIGA Technologies Inc's assets above their book value (1.41x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: SIGA Technologies Inc's assets decreased by 10.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for SIGA Technologies Inc (1996–2025)
The table below shows the annual total assets of SIGA Technologies Inc from 1996 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $219.47 Million | -10.18% |
| 2024-12-31 | $244.34 Million | -3.94% |
| 2023-12-31 | $254.35 Million | +30.41% |
| 2022-12-31 | $195.04 Million | -9.17% |
| 2021-12-31 | $214.73 Million | +43.31% |
| 2020-12-31 | $149.83 Million | -24.54% |
| 2019-12-31 | $198.57 Million | -2.40% |
| 2018-12-31 | $203.44 Million | +40.63% |
| 2017-12-31 | $144.67 Million | -10.13% |
| 2016-12-31 | $160.98 Million | -13.33% |
| 2015-12-31 | $185.73 Million | +11.63% |
| 2014-12-31 | $166.39 Million | -14.16% |
| 2013-12-31 | $193.82 Million | +83.14% |
| 2012-12-31 | $105.84 Million | +17.10% |
| 2011-12-31 | $90.38 Million | +234.35% |
| 2010-12-31 | $27.03 Million | +4.31% |
| 2009-12-31 | $25.92 Million | +194.58% |
| 2008-12-31 | $8.80 Million | -16.92% |
| 2007-12-31 | $10.59 Million | -24.52% |
| 2006-12-31 | $14.03 Million | +129.77% |
| 2005-12-31 | $6.11 Million | -0.09% |
| 2004-12-31 | $6.11 Million | +0.18% |
| 2003-12-31 | $6.10 Million | +115.53% |
| 2002-12-31 | $2.83 Million | -32.74% |
| 2001-12-31 | $4.21 Million | +31.07% |
| 2000-12-31 | $3.21 Million | -5.58% |
| 1999-12-31 | $3.40 Million | -52.11% |
| 1998-12-31 | $7.10 Million | -36.04% |
| 1997-12-31 | $11.10 Million | +1750.00% |
| 1996-12-31 | $600.00K | -- |
About SIGA Technologies Inc
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York.